Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Pieris Pharmaceuticals
Pieris Pharmaceuticals
X
LinkedIn
Trending Articles
Optimising RNA production for faster and cheaper pharmaceutical manufacturing
RNA production can be a lengthy and complex process, but the Ntensify platform could change this by diminishing development times, decreasing production costs and allowing the...
ChargePoint invest in a single-use manufacturing facility to expand product line
The single-use manufacturing facility will become fully operational in June 2024, and will support the company's trio of liquid and powder transfer devices
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Owlstone Medical bags $6.5m to optimise infectious disease diagnostic tool
The Bill & Melinda Gates Foundation has funded the bolstering of the Breath Biopsy platform, as well as research into breath biomarkers in tuberculosis (TB) and HIV
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Media
Merck is set to lead pharmaceutical licensing deals in 2018
GlobalData, a specialist data and analytics company, expects that 2018 is likely to be Merck’s year in terms of research and development collaboration
Media
Pieris Pharmaceuticals appoints new Chairman for Board of Directors
Pharmaceutical
Pieris Pharmaceuticals appoints James Geraghty to its Board of Directors
Regulatory
Commercialised anticalin inhaled treatments
Pieris Pharmaceuticals and AstraZeneca collaborate to develop and commercialise treatments for respiratory diseases
Ingredients
Pieris announces first cancer immunotherapy collaboration
Agreement with Roche leverages proprietary Anticalin technology platform
Pharmaceutical
Pieris Pharmaceuticals appoints Chief Development Officer
Louis Matis takes up the position at the biotechnology company
Research & Development
Pieris Pharmaceuticals and the University of Melbourne receive grant
To advance Anticalin-based therapeutic for inhaled delivery to treat asthmatics
Subscribe now